Phase 1 clinical trial of CPV-104
Latest Information Update: 04 Jul 2024
At a glance
- Drugs Recombinant human complement factor H (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Adverse reactions
Most Recent Events
- 03 Jul 2024 According to an Eleva media release, Eleva is preparing a first clinical study in C3G and expects to commence dosing patients in H1 2025.
- 30 May 2024 New trial record